Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829610 | 0.90 | OPRD1 (0.51) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879312 | 0.89 | OPRD1 (0.58) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879325 | 0.87 | OPRD1 (0.85) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879376 | 0.86 | OPRD1 (0.68) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879398 | 0.86 | OPRD1 (0.59) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879354 | 0.85 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879326 | 0.85 | OPRD1 (0.74) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879362 | 0.85 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879365 | 0.85 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879357 | 0.84 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395558-B1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | EP | claimed |
| US-20040152731-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | claimed |
| US-7064137-B2 | Analgesics; anxiolytic agents; gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152731-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR2C, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 8/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.